Zum Inhalt springen

San Antonio Breast Cancer Symposium

@sabcs.bsky.social did:plc:noiqwwgdlh2wyc5m5shunks3

SABCS is the world's largest gathering of doctors, researchers and scientists sharing state-of-the-art information on experimental biology, etiology, prevention, diagnosis, and therapy for breast cancer and premalignant breast diseases. www.sabcs.org

Bei Bluesky seit

Follower
1.223
Folgt
6
Posts
161
Tage in Ranglisten
0

Zusammenfassung

San Antonio Breast Cancer Symposium (@sabcs.bsky.social) ist seit 20 November 2024 auf Bluesky. Das Konto hat 1.223 Follower, folgt 6 Konten und hat 161 Posts veröffentlicht.

Ranglisten-Platzierungen

Die besten Tage, an denen Posts dieses Kontos in Debyas Tagesliste kamen.

Dieses Konto war noch in keiner Tagesrangliste.

Zuletzt gelikte Posts

Öffentliche Likes aus dem Bluesky-Netzwerk.

  • Stacey Tinianov, MPH@coffeemommy.bsky.social

    Mid-week into hot-off-the-press research results at the annual @sabcs.bsky.social Grateful to be sharing space and hugs with fellow advocates and colleagues 💗 #SABCS25

    Post anzeigen
  • Yale Cancer Center@yalecancer.bsky.social

    @ncasasanta.bsky.social presents data at #SABCS25: In advanced #breastcancer, genomic profiling shows younger women more frequently have BRCA1/2, TP53, HRD, and PD-L1 alterations, while older women more often exhibit ESR1, PIK3CA, CDH1, and higher TMB. @sabcs.bsky.social @oncoalert.bsky.social

    Post anzeigen
  • Yale Cancer Center@yalecancer.bsky.social

    Dr. Guannan Gong shares how an #AI-driven patient-matching system improved ID of eligible patients for #breastcancer trials + increased representation of under-enrolled groups. #SABCS25 @maryamlustberg.bsky.social @sabcs.bsky.social @oncoalert.bsky.social

    Post anzeigen
  • Yale Cancer Center@yalecancer.bsky.social

    New research from Dr. Lajos Pusztai #SABCS25 shows RNA levels of ESR1, PGR closely match traditional estrogen receptor/progesterone receptor test results in #breastcancer. @foundationmedicine.bsky.social @sabcs.bsky.social @oncoalert.bsky.social

    Post anzeigen
  • Yale Cancer Center@yalecancer.bsky.social

    Dr. Mariya Rozenblit highlights how C1D15 DiviTum® TKa levels can uncover early adherence issues or drug interactions during CDK4/6 inhibitor therapy. #SABCS25 Takeaway: DiviTum® TKa is a practical early biomarker to optimize breast cancer treatment outcomes. @sabcs.bsky.social

    Post anzeigen

Melde dich an, um mehr zu sehen

Blockierte Konten

Blockierungen sind auf Bluesky öffentlich.

Dieses Konto blockiert niemanden.